NASDAQ:DVAX

Dynavax Technologies Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

$9.82

-0.0800 (-0.81%)

At Close: May 22, 2025

Dynavax Technologies Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 52.98. In total, the insiders bought 1 980 187 and sold 522 745 DVAX shares in the last 100 trades.

Insider Power (Last 100 transactions)	52.98
Buy	1 980 187 Shares
Sell	522 745 Shares

Historical Insider Trades

Date	Type	Action	Person	Amount
May 12, 2025	Restricted Stock Unit	Buy	Metzinger Joseph Anthony	38 182
May 12, 2025	Option (Right to Buy)	Buy	Metzinger Joseph Anthony	31 500
May 12, 2025		Buy	Metzinger Joseph Anthony	0
Mar 24, 2025	Stock Option (Right to Buy)	Sell	Novack David F	10 000
Mar 24, 2025	Common Stock	Buy	Novack David F	10 000
Mar 24, 2025	Common Stock	Sell	Novack David F	10 000
Mar 18, 2025	Common Stock	Sell	Novack David F	14 020
Mar 07, 2025	Common Stock	Sell	Novack David F	32 764
Feb 18, 2025	Common Stock	Buy	Slebir John L	16 667
Feb 18, 2025	Common Stock	Sell	Slebir John L	5 358
Feb 18, 2025	Restricted Stock Unit	Sell	Slebir John L	16 667
Feb 18, 2025	Common Stock	Buy	Janssen Robert	11 904
Feb 18, 2025	Common Stock	Sell	Janssen Robert	4 041
Feb 18, 2025	Restricted Stock Unit	Sell	Janssen Robert	11 904
Feb 18, 2025	Common Stock	Buy	Macdonald Kelly	15 477
Feb 18, 2025	Restricted Stock Unit	Sell	Macdonald Kelly	15 477
Feb 18, 2025	Common Stock	Sell	Macdonald Kelly	4 975
Feb 18, 2025	Common Stock	Buy	Spencer Ryan	55 000
Feb 18, 2025	Common Stock	Sell	Spencer Ryan	36 528
Feb 18, 2025	Restricted Stock Unit	Sell	Spencer Ryan	55 000
Feb 18, 2025	Common Stock	Buy	Novack David F	22 620
Feb 18, 2025	Common Stock	Sell	Novack David F	10 665
Feb 18, 2025	Restricted Stock Unit	Sell	Novack David F	22 620
Feb 13, 2025	Common Stock	Buy	Spencer Ryan	62 500
Feb 13, 2025	Common Stock	Sell	Spencer Ryan	31 694

ABOUT DYNAVAX TECHNOLOGIES CORPORATION

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
UAA $5.84	11.64%	May 09
IIPR $54.61	1.70%	May 09
HBM $7.41	14.44%	May 05
PODD $257.01	24.90%	May 02
GT $9.14	21.77%	Mar 21

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by